Catalog No.
PHC89701
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CETP (Ile81-Ala311).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
CETP,Lipid transfer protein I,Cholesteryl ester transfer protein
Purification
Purified by antigen affinity column.
Accession
P11597
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Immunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study., PMID:40114074
Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis., PMID:39909173
Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention., PMID:39907207
Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?, PMID:39766344
A novel LPS binding /bactericidal permeability-increasing protein (LBP/BPI) from the scallop Argopecten purpuratus plays an essential role in host resistance to Vibrio infection., PMID:39471964
The effect of dulaglutide on glycated hemoglobin is associated with PNPLA3 Ι148Μ gene polymorphism in patients with type 2 diabetes mellitus., PMID:39179734
Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond., PMID:39070027
Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia., PMID:38866219
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better., PMID:38576462
Complex changes in serum protein levels in COVID-19 convalescents., PMID:38396092
CETP-derived Peptide Seq-1, the Key Component of HB-ATV-8 Vaccine Prevents Stress Responses, and Promotes Downregulation of Pro-Fibrotic Genes in Hepatocytes and Stellate Cells., PMID:38301446
Two decades of vaccine development against atherosclerosis., PMID:37860053
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial., PMID:37277261
Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice., PMID:36898656
Plasma Proteome Profiling of Patients With In-stent Restenosis by Tandem Mass Tag-Based Quantitative Proteomics Approach., PMID:35265678
A single-dose, implant-based, trivalent virus-like particle vaccine against "cholesterol checkpoint" proteins., PMID:34541299
Biological drug and drug delivery-mediated immunotherapy., PMID:33996408
Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice., PMID:33722697
Beneficial effects of brown fat activation on top of PCSK9 inhibition with alirocumab on dyslipidemia and atherosclerosis development in APOE*3-Leiden.CETP mice., PMID:33667684
Novel role of cholesteryl ester transfer protein (CETP): attenuation of adiposity by enhancing lipolysis and brown adipose tissue activity., PMID:33166579
Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report., PMID:33115273
No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice., PMID:32858115
The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins., PMID:32591337
Development of an effective liposomal cholesterol ester transfer protein (CETP) vaccine for protecting against atherosclerosis in rabbit model., PMID:31852350
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice., PMID:31843957
Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis., PMID:31779098
Oncostatin M reduces atherosclerosis development in APOE*3Leiden.CETP mice and is associated with increased survival probability in humans., PMID:31461490
Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice., PMID:31366894
Antisense Oligonucleotides Targeting Lipoprotein(a)., PMID:31111240
Therapeutic Intranasal Vaccine HB-ATV-8 Prevents Atherogenesis and Non-alcoholic Fatty Liver Disease in a Pig Model of Atherosclerosis., PMID:30792163
Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation., PMID:30306859
Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy., PMID:29934068
From lipid locus to drug target through human genomics., PMID:29800275
Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer., PMID:29777999
Cholesteryl ester transfer protein and its inhibitors., PMID:29487091
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice., PMID:28637178
Investigational therapies for hypercholesterolemia., PMID:28368771
A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis., PMID:28096968
New directions for pharmacotherapy in the treatment of acute coronary syndrome., PMID:27677394
Polyhedral 3D structure of human plasma very low density lipoproteins by individual particle cryo-electron tomography1., PMID:27538822
Anti-atherosclerosis effect of different doses of CETP vaccine in rabbit model of atherosclerosis., PMID:27261627
Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP., PMID:26876146
Promising new therapies for the treatment of hypercholesterolemia., PMID:26822080
Low High-Density Lipoprotein and Risk of Myocardial Infarction., PMID:26692765
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes., PMID:26548322
Higher Cardiovascular Risk in Common Variable Immunodeficiency and X-Linked Agammaglobulinaemia Patients., PMID:26183722
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs., PMID:26169307
Discovery Approaches for Novel Dyslipidemia Drugs., PMID:26135857
Prevention of fatal hepatic complication in schistosomiasis by inhibition of CETP., PMID:26060442
Modification of CETP function by changing its substrate preference: a new paradigm for CETP drug design., PMID:25616437
For research use only. Not for human or drug use.
